Evidence map›Paper›PMID 42876800›Full record

ArticleFrontiers in immunology2026

Dendritic-cell-targeting adeno-associated virus as potent cancer vaccine carriers.

Xin Wei, Xiang Li, Lixia Qi, Wenxuan Qiu, Yuxin Zhang, Liping Wu, Shutang Wei, Bofeng Luo, Menghan Shi, Chenhao Liu and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Xin Wei *The Department of Gastroenterology, The First Affiliated Hospital of Henan University, Kaifeng, Henan, China.
Xiang Li *Laboratory of Cancer Biomarkers and Liquid Biopsy, School of Pharmacy, Henan University, Kaifeng, Henan, China.
Lixia Qi *Laboratory of Cancer Biomarkers and Liquid Biopsy, School of Pharmacy, Henan University, Kaifeng, Henan, China.
Wenxuan QiuThe Department of Gastroenterology, The First Affiliated Hospital of Henan University, Kaifeng, Henan, China.
Yuxin ZhangThe Department of Gastroenterology, The First Affiliated Hospital of Henan University, Kaifeng, Henan, China.
Liping WuThe Department of Gastroenterology, The First Affiliated Hospital of Henan University, Kaifeng, Henan, China.
Shutang WeiThe Department of Gastroenterology, The First Affiliated Hospital of Henan University, Kaifeng, Henan, China.
Bofeng LuoThe Department of Gastroenterology, The First Affiliated Hospital of Henan University, Kaifeng, Henan, China.
Menghan ShiThe Department of Gastroenterology, The First Affiliated Hospital of Henan University, Kaifeng, Henan, China.
Chenhao LiuThe Department of Gastroenterology, The First Affiliated Hospital of Henan University, Kaifeng, Henan, China.
Qi YangThe Department of Gastroenterology, The First Affiliated Hospital of Henan University, Kaifeng, Henan, China.
Wenyi YangThe Department of Gastroenterology, The First Affiliated Hospital of Henan University, Kaifeng, Henan, China.
Dengke BaoThe Department of Gastroenterology, The First Affiliated Hospital of Henan University, Kaifeng, Henan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The clinical efficacy of therapeutic cancer vaccines is critically limited by the inefficient Methods: To address this issue, we developed a dendritic-cell-targeting adeno-associated virus (AAV) vector through rational capsid design. This was achieved by site-specifically inserting the high-affinity Clec9a-targeting peptide CBP-12, optimizing its flanking sequences, and introducing T491V/S662V gain-of-function mutations to synergistically enhance DC transduction. Results: The resulting vector, AAV2-mut-Peptide2, showed significantly improved tropism for and gene delivery efficiency to cross-presenting cDC1s Conclusion: Our study establishes this engineered AAV as a versatile and potent vaccine platform that effectively targets DCs, offering a promising approach for inducing robust and adaptable anti-tumor immunity.

Indexed as

Cancer VaccinesCarcinoma, HepatocellularDendritic CellsDependovirusGenetic VectorsLiver NeoplasmsAnimalsAntigens, NeoplasmCD8-Positive T-LymphocytesFemaleHumansLectins, C-TypeMiceMice, Inbred C57BLReceptors, ImmunologicReceptors, MitogenAntigens, NeoplasmCancer VaccinesClec9a protein, mouseLectins, C-TypeReceptors, ImmunologicReceptors, Mitogenadeno-associated virusantigen gene deliverycancer vaccinesdendritic cellstumor immunotherapy

Identifiers

PMID42876800
PMCPMC13662115

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.